StreetInsider.com News Articles

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 07:59:00 -0400

BOSTON, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to five newly-hired, non-executive employees on October 1, 2026. The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consist of options to purchase an aggregate of 144,400 Damora ordinary shares with a

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Fri, 02 Oct 2026 07:59:00 -0400

The inducement grants consist of options to purchase an aggregate of 144,400 Damora ordinary shares with a

Form 4 Damora Therapeutics, For: Sep 25 Filed by: Jarrett Jennifer

Mon, 28 Sep 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260928/27109888.html

Damora Therapeutics (DMRA) PT Raised to $60 at Guggenheim

Fri, 25 Sep 2026 06:27:00 -0400

(Updated - September 25, 2026 6:27 AM EDT)

Guggenheim raised its price target on Damora Therapeutics (NASDAQ: DMRA) to $60.00 (from $40.00) while maintaining a Buy rating.

The analyst commented: "We think peak sales expectations of mCALR antibodies in myelofibrosis (MF) are too low because they are anchored to a Jakafi sales proxy rather than a view of what a next-generation targeted therapy can turn that market into. This research note offers a view of that new market potential, and we now model the mCALR class achieving global MF sales of ~$3bn (from ~$1bn), which increases our DMRA price target to $60

Damora Therapeutics (DMRA) PT Raised to $60 at Guggenheim

Fri, 25 Sep 2026 06:27:00 -0400

(Updated - September 25, 2026 6:27 AM EDT)

Guggenheim raised its price target on Damora Therapeutics (NASDAQ: DMRA) to $60.00 (from $40.00) while maintaining a Buy rating.

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 03 Sep 2026 08:00:00 -0400

BOSTON, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Damora Therapeutics, Inc. (NASDAQ: DMRA) (“Damora”), a biotechnology company working to fundamentally redefine care for patients with blood disorders, today announced that it granted equity awards to three newly-hired, non-executive employees on September 1, 2026. The inducement grants were approved by Damora’s independent Compensation Committee of its Board of Directors and were made as material inducements to such individuals’ acceptance of employment with Damora in accordance with Nasdaq Listing Rule 5635(c)(4).

The inducement grants consist of options to purchase an aggregate of 135,400 Damora ordinary shares with a 10-year

Damora Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 03 Sep 2026 08:00:00 -0400

The inducement grants consist of options to purchase an aggregate of 135,400 Damora ordinary shares with a 10-year

TD Cowen Assumes Damora Therapeutics (DMRA) at Buy

Sat, 22 Aug 2026 07:54:20 -0400

TD Cowen analyst Tyler Van Buren assumes coverage on Damora Therapeutics (NASDAQ: DMRA) with a Buy rating.

For an analyst ratings summary and ratings history on Damora Therapeutics click here. For more ratings news on Damora Therapeutics click here.

Shares of Damora Therapeutics closed at $30.82 yesterday.

Form 4 Damora Therapeutics, For: Aug 12 Filed by: Cheng Andrew

Thu, 13 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260813/26922481.html

Form 4 Damora Therapeutics, For: Aug 12 Filed by: Cheng Andrew

Thu, 13 Aug 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260813/26922481.html

Form 3 Damora Therapeutics, For: Aug 12 Filed by: Cheng Andrew

Thu, 13 Aug 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260813/26922407.html

Form 3 Damora Therapeutics, For: Aug 12 Filed by: Cheng Andrew

Thu, 13 Aug 2026 16:55:00 -0400

si-local-file:///var/storage/secattach/20260813/26922407.html

Form EFFECT Damora Therapeutics,

Thu, 13 Aug 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260813/26915718.html

Form EFFECT Damora Therapeutics,

Thu, 13 Aug 2026 06:06:00 -0400

si-local-file:///var/storage/secattach/20260813/26915718.html

Form S-8 POS Damora Therapeutics,

Mon, 10 Aug 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260810/26899304.html

Form S-8 POS Damora Therapeutics,

Mon, 10 Aug 2026 17:28:00 -0400

si-local-file:///var/storage/secattach/20260810/26899304.html

Form S-8 POS Damora Therapeutics,

Mon, 10 Aug 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20260810/26899289.html

Form S-8 POS Damora Therapeutics,

Mon, 10 Aug 2026 17:27:00 -0400

si-local-file:///var/storage/secattach/20260810/26899289.html

Form POSASR Damora Therapeutics,

Mon, 10 Aug 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260810/26899263.html

Form POSASR Damora Therapeutics,

Mon, 10 Aug 2026 17:25:00 -0400

si-local-file:///var/storage/secattach/20260810/26899263.html

Form S-8 POS Damora Therapeutics,

Mon, 10 Aug 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260810/26899237.html

Form S-8 POS Damora Therapeutics,

Mon, 10 Aug 2026 17:23:00 -0400

si-local-file:///var/storage/secattach/20260810/26899237.html

Form S-8 POS Damora Therapeutics,

Mon, 10 Aug 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260810/26899206.html

Form S-8 POS Damora Therapeutics,

Mon, 10 Aug 2026 17:20:00 -0400

si-local-file:///var/storage/secattach/20260810/26899206.html

Form S-8 POS Damora Therapeutics,

Mon, 10 Aug 2026 17:19:00 -0400

si-local-file:///var/storage/secattach/20260810/26899191.html